{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T01:56:31Z","timestamp":1780970191243,"version":"3.54.1"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["72074123"],"award-info":[{"award-number":["72074123"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001547","name":"China Medical Board","doi-asserted-by":"publisher","award":["17-277"],"award-info":[{"award-number":["17-277"]}],"id":[{"id":"10.13039\/100001547","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The purpose of this study was to evaluate the cost-effectiveness and budget impact of fosaprepitant (FosAPR)-containing regimen for the prevention of chemotherapy-induced nausea and vomiting (CINV) among patients receiving high emetogenic chemotherapy (HEC) from the Chinese payer's perspective.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A decision tree model was established to measure the 5-day costs and health outcomes between the APR-containing regimen (aprepitant, granisetron, and dexamethasone) and FosAPR-containing regimen (fosaprepitant, granisetron, and dexamethasone). Clinical data were derived from a randomized, double-blind controlled trial on Chinese inpatients who received HEC. Quality-adjusted life-years (QALYs) were used to estimate the utility outcomes and the incremental cost-effectiveness ratio (ICER) was calculated to assess the economics of FosAPR. A static budget impact model was developed to assess the impact of FosAPR as a new addition to the National Reimbursement Drug List (NRDL) on the medical insurance fund within 3 years in Nanjing, China.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Compared with APR, FosAPR had a mean health-care savings of \u00a5121.56 but got a reduction of 0.0001815 QALY, resulting in an ICER of \u00a5669926.19 per QALY. Deterministic sensitivity analysis revealed that the cost of APR was the most influential factor to the ICER. The cost of FosAPR and the complete control rate of the delayed period also had a high impact on the results. According to the probabilistic analysis, the acceptability of FosAPR was more than 80% when the Chinese willingness-to-pay (WTP) was \u00a5215,999. FosAPR would lead to a 3-year medical insurance payment increase of \u00a51.84 million compared with \u00a51.49 million before FosAPR entered NRDL in Nanjing. The total budget increased with a cumulative cost of \u00a5694,829 and covered an additional 341 patients who benefited from FosAPR in Nanjing. Deterministic sensitivity analysis showed that the model of budget impact analysis was stable.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>FosAPR had a similar treatment effect to APR but was cost-effective in China at the current WTP threshold. The total budget of medical insurance payments of Nanjing slightly increased year by year after the inclusion of FosAPR. Its inclusion in the NRDL would be acceptable and also expand the coverage of patients who benefited from FosAPR.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2022.913129","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T05:38:45Z","timestamp":1657604325000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Economic Value of Fosaprepitant-Containing Regimen in the Prevention of Chemotherapy-Induced Nausea and Vomiting in China: Cost-Effectiveness and Budget Impact Analysis"],"prefix":"10.3389","volume":"10","author":[{"given":"Xinglu","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwen","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuolin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningli","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"key":"B3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/IGC.0b013e318234f9ee","article-title":"impact of chemotherapy-induced nausea and vomiting on quality of life in Indonesian patients with gynecologic cancer","volume":"22","author":"Perwitasari","year":"2012","journal-title":"Int J Gynecol Cancer."},{"key":"B4","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Antiemesis Version 2.2019","year":"2019"},{"key":"B5","doi-asserted-by":"publisher","first-page":"946","DOI":"10.19401\/j.cnki.1007-3639.2018.12.011","article-title":"Shanghai expert consensus on the management of chemotherapy-induced nausea and vomiting (Version 2018)","volume":"28","year":"2018","journal-title":"China Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.13286\/j.cnki.chinhosppharmacyj.2018.12.19","volume":"38","author":"Zhang","year":"2018","journal-title":"Chin Hosp Pharm J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1200\/JCO.2015.64.3635","article-title":"Antiemetics: American Society of Clinical Oncology Focused Guideline Update","volume":"34","author":"Hesketh","year":"2016","journal-title":"J Clin Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.ejca.2005.01.024","article-title":"The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials","volume":"41","author":"Warr","year":"2005","journal-title":"Eur J Cancer."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s00520-018-4403-y","article-title":"Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial","volume":"27","author":"Tsuji","year":"2019","journal-title":"Support Care Cancer."},{"key":"B10","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10147-015-0908-2","article-title":"Control of chemotherapy-induced nausea in patients receiving outpatient cancer chemotherapy","volume":"21","author":"Iihara","year":"2016","journal-title":"Int J Clin Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1080\/07420528.2017.1295978","article-title":"Late chronotypes are associated with neoadjuvant chemotherapy-induced nausea and vomiting in women with breast cancer","volume":"34","author":"Lee","year":"2017","journal-title":"Chronobiol Int."},{"key":"B12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3389\/fphar.2020.00329","article-title":"Patient-related risk factors for chemotherapy-induced nausea and vomiting: a systematic review","volume":"11","author":"Mosa","year":"2020","journal-title":"Front Pharmacol."},{"key":"B13","first-page":"263","article-title":"Guidelines for the prevention and treatment of vomiting associated with tumor therapies (Version 2014)","volume":"19","author":"Yu","year":"2014","journal-title":"Chin Clin Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S1470-2045(15)70061-6","article-title":"Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial","volume":"16","author":"Kang","year":"2015","journal-title":"Lancet Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ctrv.2012.09.002","article-title":"Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types","volume":"39","author":"Aapro","year":"2013","journal-title":"Cancer Treat Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s12325-018-0862-2","article-title":"Efficacy, tolerability and pharmacokinetic impact of aprepitant in sarcoma patients receiving ifosfamide and doxorubicin chemotherapy: a randomized controlled trial","volume":"36","author":"Xiong","year":"2019","journal-title":"Adv Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1517\/17425255.2010.513970","article-title":"Pharmacokinetic evaluation of fosaprepitant dimeglumine","volume":"6","author":"Colon-Gonzalez","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ejphar.2013.09.073","article-title":"International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice","volume":"722","author":"Jordan","year":"2014","journal-title":"Eur J Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1524-4733.2006.00141.x","article-title":"Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy","volume":"10","author":"Moore","year":"2007","journal-title":"Value Health."},{"key":"B20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2147\/CMAR.S44539","article-title":"Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK","volume":"5","author":"Humphreys","year":"2013","journal-title":"Cancer Manag Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s00520-007-0349-1","article-title":"Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium","volume":"16","author":"Annemans","year":"2008","journal-title":"Support Care Cancer."},{"key":"B22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ejca.2006.09.019","article-title":"Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany","volume":"43","author":"Lordick","year":"2007","journal-title":"Eur J Cancer."},{"key":"B23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/ajco.12170","article-title":"Economic analysis of aprepitant-containing regimen to prevent chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Hong Kong","volume":"10","author":"Chan","year":"2014","journal-title":"Asia Pac J Clin Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.vhri.2012.03.002","article-title":"Aprepitant for patients receiving highly emetogenic chemotherapy: an economic analysis for Singapore","volume":"1","author":"Lopes","year":"2012","journal-title":"Value Health Reg Issues."},{"key":"B25","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.clinthera.2019.03.011","article-title":"Comparative cost-utility analysis between aprepitant- and fosaprepitant-containing regimens to prevent chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan","volume":"41","author":"Kashiwa","year":"2019","journal-title":"Clin Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jval.2017.12.017","article-title":"The ICER value framework: integrating cost effectiveness and affordability in the assessment of health care value","volume":"21","author":"Pearson","year":"2018","journal-title":"Value Health"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e12668","DOI":"10.1111\/ecc.12668","article-title":"Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people: A randomized, double-blind, phase III study","volume":"26","author":"Yang","year":"2017","journal-title":"Eur J Cancer Care."},{"key":"B28","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00520-004-0710-6","article-title":"Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer","volume":"13","author":"Sun","year":"2005","journal-title":"Support Care Cancer."},{"key":"B29","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1186\/s12913-019-4281-0","article-title":"Cost-utility analysis of palonosetron in the antiemetic regimen for cisplatin-containing highly emetogenic chemotherapy in Japan","volume":"19","author":"Kashiwa","year":"2019","journal-title":"BMC Health Serv Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1524-4733.2007.00187.x","article-title":"Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices\u2013budget impact analysis","volume":"10","author":"Mauskopf","year":"2007","journal-title":"Value Health."},{"key":"B31","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2165\/00019053-200826060-00003","article-title":"Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada","volume":"26","author":"Marshall","year":"2008","journal-title":"Pharmacoeconomics."},{"key":"B32","year":"","journal-title":"Nanjing Statistical Yearbook 2020"},{"key":"B33","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e015645","DOI":"10.1136\/bmjopen-2016-015645","article-title":"Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy","volume":"7","author":"Restelli","year":"2017","journal-title":"BMJ Open."},{"key":"B35","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40880-019-0368-6","article-title":"Current cancer situation in China: good or bad news from the 2018 global cancer statistics?","volume":"39","author":"Feng","year":"2019","journal-title":"Cancer Commun."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JGO.18.00219","article-title":"Temporal changes in head and neck cancer incidence in Thailand suggest changing oropharyngeal epidemiology in the region","volume":"5","author":"Argirion","year":"2019","journal-title":"J Glob Oncol."},{"key":"B37","first-page":"4251","article-title":"Incidence and mortality of testicular cancer and relationships with development in Asia","volume":"17","author":"Sadeghi","year":"2016","journal-title":"Asian Pac J Cancer Prev."},{"key":"B38","doi-asserted-by":"publisher","first-page":"723","DOI":"10.13748\/j.cnki.issn1007-7693.2019.06.016","article-title":"Budget impact analysis of afatinib in advanced non-small cell lung cancer patients with EGFR mutation","volume":"36","author":"Fu","year":"2019","journal-title":"Chin J Mod Appl Pharm"},{"key":"B39","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","article-title":"Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force","volume":"17","author":"Sullivan","year":"2014","journal-title":"Value Health."},{"key":"B40","volume-title":"Guidelines of Chinese Society of Clinical Oncology (CSCO) Prevention & Treatment of Nausea and Vomiting Caused by Antitumor Therapies (Version 2019)","year":"2019"},{"key":"B41","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3760\/cma.j.cn112152-20200120-00049","article-title":"Guidelines for clinical diagnosis and treatment of lung cancer of Chinese Medical Association (Version 2019)","volume":"42","year":"2020","journal-title":"Chin J Oncol."},{"key":"B42","unstructured":"NCCN Clinical Practice Guidelines in Oncology-Gastric Cancer (Version 3.2020)"},{"key":"B43","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3332\/ecancer.2015.567","article-title":"Comparative evaluation of triplet antiemetic schedule versus doublet antiemetic schedule in chemotherapy-induced emesis in head and neck cancer patients","volume":"9","author":"Kaushal","year":"2015","journal-title":"Ecancermedicalscience."},{"key":"B44","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.oraloncology.2010.03.004","article-title":"Advances in chemotherapy for head and neck cancer","volume":"46","author":"Bhide","year":"2010","journal-title":"Oral Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1007\/s00120-013-3251-0","article-title":"Update Erstlinien- und Rezidivchemotherapie beim Hodentumor [Update on first-line and relapse chemotherapy for testicular cancer]","volume":"52","author":"Lorch","year":"2013","journal-title":"Urologe A."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet."},{"key":"B47","doi-asserted-by":"publisher","first-page":"184","DOI":"10.13699\/j.cnki.1001-6821.2015.03.008","article-title":"Efficacy and safety of pirarubicin hot perfusion combined with systemic chemotherapy in the treatment of advanced bladder cancer","volume":"31","author":"Luo","year":"2015","journal-title":"Chin J Clin Pharmacol."},{"key":"B48","unstructured":"Urban Medical Insurance Drug List Query"},{"key":"B49","unstructured":"Medical Security Development Statistics Nanjing 20202021"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.913129\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T05:39:01Z","timestamp":1657604341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.913129\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,12]]},"references-count":49,"alternative-id":["10.3389\/fpubh.2022.913129"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2022.913129","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,12]]},"article-number":"913129"}}